Expanded Disability Status Scale

From WikiMD's WELLNESSPEDIA

Diagram of the Expanded Disability Status Scale

The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis (MS) and monitoring changes in the level of disability over time. The scale was developed by John F. Kurtzke in 1983 and is widely used in clinical trials and in the assessment of patients with MS.

Description[edit]

The EDSS quantifies disability in eight Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. The FS include:

  • Pyramidal (motor function)
  • Cerebellar (coordination)
  • Brainstem (speech and swallowing)
  • Sensory (touch and pain)
  • Bowel and bladder function
  • Visual function
  • Cerebral (mental) function
  • Other

The EDSS score ranges from 0 to 10 in 0.5 increments, with 0 being normal neurological examination and 10 being death due to MS. Scores from 1.0 to 4.5 refer to people with MS who are fully ambulatory, while scores from 5.0 to 9.5 are defined by the impairment to ambulation.

Scoring[edit]

The scoring is based on a neurological examination and the patient's ability to walk. The scale is heavily weighted towards ambulation, with higher scores indicating greater disability:

  • 0.0: Normal neurological exam
  • 1.0-1.5: No disability, minimal signs in one FS
  • 2.0-2.5: Minimal disability in one FS
  • 3.0-3.5: Moderate disability in one FS
  • 4.0-4.5: Significant disability but able to walk without aid
  • 5.0-5.5: Disability severe enough to impair full daily activities
  • 6.0-6.5: Requires a walking aid
  • 7.0-7.5: Restricted to wheelchair
  • 8.0-8.5: Restricted to bed or chair
  • 9.0-9.5: Confined to bed, unable to communicate effectively
  • 10.0: Death due to MS

Limitations[edit]

The EDSS is criticized for its emphasis on ambulation and its insensitivity to changes in other areas of disability, such as cognitive function. It may not fully capture the impact of MS on a patient's quality of life. Despite these limitations, it remains a standard tool in both clinical practice and research.

Related pages[edit]


Demyelinating diseases of the central nervous system
Signs and symptoms
Investigations and diagnosis
Approved treatment
Other treatments

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Expanded_Disability_Status_Scale&oldid=6626180"